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There is a need to develop vaccines with the potential
for global use against bacterial infectious diseases.
These should be inexpensive to produce, stable in the
absence of refrigeration, safe and efficacious, and able
to be given orally or intranasally rather than by injec-
tion. Here, I will focus on efforts to develop live attenu-
ated bacterial vaccines and the use of recombinant
attenuated bacteria to induce protective immunity
against heterologous bacterial pathogens. I will not dis-
cuss bacterial vaccine vectors expressing viral, parasite,
or fungal antigens, since lack of posttranslational mod-
ification and improper folding generally lead to induc-
tion of immune responses that are not protective,
although induction of cell-mediated immunity can
often be protective. Also omitted will be a discussion of
the use of attenuated bacterial vaccine vectors for the
delivery of DNA vaccines, wherein problems of process-
ing of viral, parasite, and fungal antigens in bacteria are
rectified by the synthesis and modification of these anti-
gens within the eukaryotic cell. Lastly, although I
acknowledge their value, especially in the developed
world, I will not dwell on progress in the development
of subunit and conjugate vaccines. Studies of such vac-
cines, however, often provide valuable information on
identification and characterization of protective anti-
gens that can be expressed in live recombinant attenu-
ated bacterial vaccines of the kind I consider below.
Attributes of safe and effective 
live bacterial vaccines
The bacterial vaccine or antigen delivery vector. Attenuation
should be sufficient to decrease if not eliminate induc-
tion of undesirable disease symptoms. In this regard,
the nutritional status and health of the population to
be vaccinated should be considered. The attenuation
should be an inherent property of the bacterial vaccine
and not be dependent on fully functional host defens-
es and immune response capabilities. The attenuation
should not be reversible by diet or by host modification
of diet constituents, including by host-resident micro-
bial flora. The attenuation should not lead to the devel-
opment of a persistent carrier state for the vaccine.
However, it is conceivable that there may be situations
in which a persisting live vaccine could be beneficial.
The attenuated vaccine should be sufficiently invasive
and persistent to stimulate both strong primary and
lasting memory immune responses.
A vaccine should also be designed to minimize tissue
damage that is not needed to induce an effective
immune response. For example, vaccines for enteric
pathogens must access the gut-associated lymphoid tis-
sue (GALT) via invasion and transcytosis through M
cells. However, attachment to and invasion into ente-
rocytes can lead to undesirable diarrheal episodes that
do not contribute to the desired immune response. As
even attenuated vaccine strains may cause disease in a
few unlucky individuals, safety considerations dictate
that any live bacterial vaccine should be susceptible to
all clinically useful antibiotics. Lastly, the attenuated
vaccine should possess some containment features to
reduce its shedding and/or survival in nature to pre-
clude vaccination of individuals who did not elect to be
vaccinated. However, persistence of a live vaccine with
potential for individual-to-individual spread could
have a positive public health benefit, as is probably the
case for vaccination against polio.
The plasmid vector component. Stability of protective
antigen expression in vivo is essential for recombinant
vaccine efficacy. Insertion of genes into the chromo-
some can increase stability, but the level of antigen
expression is generally too low to stimulate an adequate
immune response. Since the level of protein synthesis in
bacteria is very much dependent upon gene copy num-
ber, antigen production can be vastly increased by use
of multicopy plasmid vectors. In this case, the use of a
balanced-lethal host-vector system wherein the plasmid
possesses a gene complementing a chromosomal dele-
tion mutation of a vital gene, such as for cell wall syn-
thesis or DNA stability or replication, ensures that the
plasmid is maintained (1). An alternate approach to
ensuring retention of the plasmid vector is the “Hok-
Sok” strategy, which also results in bacterial cell death
if the plasmid is lost (2). When a plasmid vector with
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high copy number is used, the level of expression of the
gene encoding the vector-selective marker can be far in
excess of that necessary for maintenance of the vector.
In these instances, overexpression of such a gene prod-
uct further attenuates the vaccine, presumably due to
the added energy drain on the recombinant vaccine. To
address this problem, the selective marker gene can be
designed to include a ribosome-binding recognition
sequence but no promoter (3). As a safety consideration,
it is desirable that plasmid vectors possess some con-
tainment features to minimize the possibility of trans-
fer to and maintenance in other bacterial species. The
vector should therefore be nonconjugative, should
preferably be nonmobilizable, should possess a narrow
replicon host range, and should not specify resistance
to any antibiotic.
In general, the level of antigen synthesis can be lower
when a Th1 cell-mediated immunity-type (CMI-type)
response is desired but must be much higher if Th2
mucosal and systemic antibody responses are neces-
sary. Promoters driving the expression of foreign anti-
gens have often been constitutive (4), but constant
antigen synthesis may decrease vaccine fitness to
result in increased attenuation and decreased
immunogenicity. Improved results have frequently
been observed by use of the nirB (5), pagC (6), and
dmsA (7) Salmonella promoters that initiate transcrip-
tion at higher levels in vivo. Antigen expression can
also be delayed until after the vaccine has invaded
lymphoid tissues by use of a regulatory cascade with
araC PBAD–controlled expression (8) of a repressor
whose synthesis is dependent on the presence of ara-
binose during in vitro cultivation. In this case, the
antigen gene is coupled to a promoter with transcrip-
tion repressed by the araC PBAD–regulated repressor.
Since there is no free arabinose in vertebrate tissues,
the foreign antigen gene is eventually de-repressed in
vivo as the repressor is diluted out as a consequence
of vaccine cell division.
The immune response to a protective antigen can be
influenced by the location of the antigen. Although
good immune responses have been observed for anti-
gens retained in the cytoplasm or secreted into the
periplasm of Gram-negative vaccines (9), placement on
the surface or secretion into the supernatant fluid
making use of heterologous (10) or homologous (11)
secretion mechanisms can further enhance the level
and type of immune response induced. In addition, by
employing the type III secretion apparatus of Salmonel-
la and Yersinia, antigens with T cell epitopes can be
delivered into the cytoplasm of antigen-presenting cells
within the immunized eukaryotic host, resulting in a
CD8-restricted CTL response (12).
The host-vector combination. The synthesis of pathogen
antigens by recombinant attenuated host-vector anti-
gen delivery systems can contribute to further attenu-
ation to reduce immunogenicity (13), another impor-
tant consideration in vaccine design. To enhance the
likelihood of sufficient colonization and persistence in
lymphoid tissues to stimulate protective immunity, the
growth properties of the vaccine construct should
match those of the host-vector control not expressing
the antigen. The recombinant system should also be
designed to maximize the immune response to the for-
eign antigen(s) and minimize the competing immune
responses to bacterial vector antigens.
Attenuated bacterial vaccines
Mycobacterium bovis Bacillus Calmette-Guérin (BCG), a
vaccine to prevent Mycobacterium tuberculosis infection,
was the first and continues to be the most widely used
live bacterial vaccine in the world. Nevertheless, M.
tuberculosis infects one-third of the human population
and causes 2 million deaths each year. The strains of
BCG used as vaccines have recently been carefully char-
acterized (14) and shown to lack expression of certain
antigens present in M. tuberculosis that might be impor-
tant for protective immunity. The means of achieving
attenuation by repetitive culture passage likely led to
a number of genetic changes that not only contribute
to attenuation but also reduce immunogenicity. Since
M. tuberculosis infection often results in a carrier state
with reactivation many years later, it is critical, in the
development of new live, attenuated M. tuberculosis vac-
cine candidates, that one preclude the creation of a
vaccine that can be as persistent in a hidden form as M.
tuberculosis is.
Salmonella typhi Ty21a is a widely used licensed live
vaccine that is exceedingly safe but requires three to
four immunizations to induce long-term (at least 6–7
years) protective immunity in two-thirds of individu-
als immunized (15). Newer, more immunogenic, live S.
typhi vaccines are currently being clinically evaluated
with the goal of developing an attenuated S. typhi vac-
cine that can induce protective immunity in a high
percentage of individuals with a single dose. This
effort has been hampered by the fact that most means
of attenuation, with one exception (phoPQ), that were
effective in attenuating Salmonella typhimurium and
rendering it highly immunogenic in mice fail to atten-
uate S. typhi sufficiently in humans (16, 17). For exam-
ple, S. typhi strains with double defined deletion muta-
tions in aro genes that possess requirements for a
number of vitamin cofactors theoretically unavailable
in vertebrates. Such strains should therefore be unable
to grow for more than seven to ten generations in vivo.
Nevertheless, positive blood cultures with fevers are
observed when high doses of the double aro vaccine are
administered to human volunteers (18). This unac-
ceptable level of reactogenicity has been corrected by
introduction of an additional mutation, htrA, elimi-
nating a heat shock protease (19), which confers addi-
tional attenuation without sacrificing too much
immunogenicity (but see ref. 20). Two such double aro
htrA vaccine candidates are being clinically evaluated
(21). Ty800, which is very likely the best-attenuated S.
typhi vaccine candidate, has a defined deletion muta-
tion of the two-component virulence-regulating genes,
phoPQ. In human trials, Ty800 induced high-level
immune responses with a single dose and without
adverse side effects, except for diarrhea in a small num-
ber of individuals (22).
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The live attenuated Bacillus anthracis strain Sterne,
licensed as a veterinary vaccine, was used for human
immunization in the former Soviet Union but was too
reactogenic (23). New, improved, live attenuated B.
anthracis vaccines have given promising results in induc-
ing protective immunity in guinea pigs (24, 25) but
have yet to undergo clinical evaluation in humans.
Development of a live attenuated Shigella vaccine that
is sufficiently attenuated to be nonreactogenic yet ade-
quately invasive to be highly immunogenic has been
attempted for over 30 years. Due to substantial progress
in understanding the molecular genetic basis of viru-
lence of Shigella since the early 1980s, there are now two
candidate vaccines with defined attenuating deletion
mutations that induce protective immunity to Shigella
challenge in humans without severe associated diar-
rheal symptoms (26, 27). Additional clinical trials on
these vaccines are likely. Nevertheless, most vaccine
development work has been with specific Shigella flexneri
serotypes (of which there are 12), and serotype-specific
immunity is important. In addition, severe dysentery is
caused by Shigella dysenteriae and less severe but more
prevalent dysentery by S. sonnei and S. boydii. Develop-
ment of effective vaccines to prevent the global Shigella
infections of 1 million or more each year, caused by
some 38 serotypes, will therefore not be easily achieved.
Two live attenuated Vibrio cholera vaccine candidates
have been constructed and clinically evaluated, and
one, CVD 103-HgR, is now commercially available (28).
Both of these vaccines possess defined deletion muta-
tions that preclude the ability to express cholera toxin
as well as some of the other accessory toxins that con-
tribute somewhat to the diarrhea caused by V. cholera
infection. Although much effort has gone into the
design of these strains, it is difficult to see how these
noninvasive candidate vaccines will induce a long-term
mucosal or systemic immune memory. The very fact
that the vaccine strains must persist in the intestinal
tract to stimulate an immune response, and that they
do so by the expression of toxin-coregulated pili, indi-
cates that some diarrhea will result from immuniza-
tion, since nontoxigenic strains of bacteria that possess
the ability to express the pilus adhesins necessary for
colonization can still cause significant diarrhea and
sometimes death in animals (29).
Attenuated recombinant bacterial 
host-vector systems
Strains of S. typhimurium and S. typhi were first used as
recombinant vectors for antigen delivery (4, 9), and
BCG was later developed as an antigen delivery vector
(30). Most recently, attenuated derivatives of S. flexneri,
Listeria monocytogenes, and B. anthracis are being evaluat-
ed as recombinant antigen delivery vaccines.
Over 15 years of research, with a substantial and
ever-increasing pace of published information,
explores the use of attenuated S. typhimurium and S.
typhi antigen delivery vaccines. Although recombinant
attenuated S. typhimurium strains expressing a diversi-
ty of antigens from various types of pathogens have
often induced protective immunity in mice and a
number of agriculturally important animals, recom-
binant attenuated S. typhi Ty2 strains evaluated in
human volunteers have induced diminished immune
responses to the Salmonella vector and insignificant or
nonexistent immune responses to expressed antigens
from several different pathogens (31–33). Although
there are several possible explanations, one significant
problem may be the choice of the S. typhi antigen deliv-
ery strain, Ty2. We have demonstrated in S. typhimuri-
um that chromosomal RpoS-regulated genes are nec-
essary for invasion into and colonization of M cells
overlying the GALT (34). In accord with this, rpoS
mutants of S. typhimurium, with or without the viru-
lence plasmid that possesses RpoS-regulated genes
that play no role in colonization of the GALT, exhibit
diminished immunogenicity, an observation con-
firmed by others (35). We demonstrated the same
defect in dependence on RpoS-regulated chromoso-
mal genes for effective colonization of lymphoid tis-
sues, presumably the nasal-associated lymphoid tissue
and bronchial-associated lymphoid tissue, following
intranasal immunization in mice. Unfortunately, S.
typhi Ty2, which was isolated in 1918 and maintained
in the laboratory ever since, possesses an rpoS allelic
defect that is also present in the not-so-immunogenic
licensed S. typhi Ty21a vaccine. It is known that RpoS+
S. typhi strains are more virulent for human volunteers
than are the S. typhi Ty2 derivatives attenuated by the
same mutations (18). Use of RpoS+ S. typhi antigen
delivery vectors will therefore necessitate degrees of
attenuation in excess of what is necessary to attenuate
S. typhi Ty2 strains for humans, but these means of
attenuation must not compromise immunogenicity.
Despite these setbacks, results with recombinant
attenuated S. typhimurium vaccines in animals suggest
that recombinant attenuated S. typhi vaccines could be
developed to protect against infections due to Hepati-
tis B virus (HBV), papillomaviruses, Streptococcus pneu-
moniae, Helicobacter pylori, Yersinia pestis, human entero-
toxigenic and Escherichia coli strains, M. tuberculosis, L.
monocytogenes, B. anthracis, Clostridium tetani, and Clostrid-
ium difficile. In addition, some progress is being made in
developing vaccines to protect against infections due to
Chlamydia, Rickettsia, Francisella tularensis, Neisseria menin-
gitidis, Brucella, and Porphyromonas. One of the more tan-
talizing challenges is to develop a recombinant attenu-
ated multivalent vaccine that would substitute for the
injectable DPT vaccines (36). Fragment C of C. tetani
has been expressed in attenuated Salmonella in mice,
using a codon-optimized sequence and induced pro-
tective immunity to C. tetani toxin challenge. It is the
only antigen delivered by an attenuated S. typhi Ty2
strain to induce a modest level of immunity in human
volunteers (37). Research on expression of the
Corynebacterium diphtheriae CRM 197 in S. typhimurium
and S. typhi looks encouraging (38). A number of Bor-
detella pertussis protective antigens have been expressed
in recombinant attenuated S. typhimurium, and signifi-
cant immune responses in mice have been observed.
Certainly, a multivalent recombinant attenuated S.
typhi expressing all of these antigens would result in a
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vaccine that could be administered orally or intranasal-
ly and would do much to reduce mortality due to these
pathogens in the developing world.
Since phagocytic cells do not readily lyse mycobacte-
rial cells, BCG or other attenuated mycobacterial
strains do not seem promising as antigen delivery vec-
tors unless the expressed antigens can be secreted from
the cells. In the case of protective antigens from Borre-
lia burgdorferi, this approach has successfully induced
protection in mice, but it failed to induce antibody
responses to the Borrelia OspA antigen in human vol-
unteers (39). Secretion of M. tuberculosis antigens by
BCG to induce protection against M. tuberculosis chal-
lenge in guinea pigs has also been achieved (40). Use of
recombinant attenuated L. monocytogenes (41), B.
anthracis (42), and S. flexneri (43) as antigen delivery vec-
tors is hampered by lack of a suitable animal host for
developmental research, the reliance on results with
injected candidate recombinant vaccines, and/or the
need to develop strains that are attenuated, nonreacto-
genic, and highly immunogenic in human volunteers.
Antigen selection
Identification of protective antigens of a pathogen to
express in a recombinant attenuated bacterial vaccine
is not an easy task. Presence of antibodies in a host sur-
viving infection can offer clues. However, a high-level
antibody response does not always correlate with pro-
tection. Of course, if one can obtain an mAb to an anti-
gen that can passively protect against the pathogen,
that is a good sign that that antigen is likely to induce
a protective response. Similarly, the identification of
antigen-specific T cell populations whose passive trans-
fer can induce protective immunity will also identify
candidate antigens for vaccine development. Evidence
that inability to express an antigen due to mutation is
associated with avirulence is another useful criteria for
antigen selection especially if the antigen is surface-
localized or secreted. 
Many protective antigens gain access to antigen-pre-
senting pathways, and one can employ genomics min-
ing with algorithms to identify subsets of proteins that
are secreted by various secretion pathways or are sur-
face-localized. For example, antigens delivered by the
type III secretion system of various pathogens such as
Salmonella and Yersinia are delivered to the cytoplasm of
host cells to result in CD8-restricted CTL responses
(12). This result may also be true for proteins secreted
by other pathogens such as Mycobacterium species, if
these proteins are secreted into the cytoplasm of cells
within the infected individual. Also, if a surface antigen
from one pathogen is found to induce protective
immunity, one can search by computer for homologs
in other pathogens that can be evaluated for their abil-
ity to induce protective immune responses.
There is a possibility that given protective antigen is
synthesized only in vivo, with the gene encoding it
responding to some stress or signal. Such antigens are
not expressed during in vitro cultivation. Genetic
screens such as In Vivo Expression Technology (IVET)
(44), Signature-Tagged Mutagenesis (STM) (45), and
Selective Capture of Transcribed Sequences (SCOTS)
(46) can be useful in identifying in vivo–expressed
genes encoding proteins essential for survival of the
pathogen in vivo. Proteins constitutively synthesized
by recombinant clones of genes uniquely expressed in
vivo can then be used to recognize either antibodies
or lymphocyte populations responding to that anti-
gen. Proteomic analysis, quantitating proteins syn-
thesized when the pathogen is in an in vivo compart-
ment or in cells in culture, can identify proteins
synthesized in the greatest amounts. Such proteins
have a higher likelihood of inducing immune
responses may or may not be protective.
Biotechnology and vaccine design
Most articles describing design of recombinant attenu-
ated vaccines omit mention of biotechnological means
to improve the performance of the recombinant atten-
uated antigen delivery vaccine. One significant excep-
tion is the consideration that has been given to the pro-
moter sequence used to drive expression of a
plasmid-encoded protective antigen. In this regard, use
of the nirB promoter, which functions optimally under
the anaerobic conditions encountered in vivo, has given
very promising results with recombinant attenuated Sal-
monella vaccine constructs (5). Often ignored among
vaccine properties, codon usage patterns have species-
specific differences, and codons in genes specifying an
antigen from a heterologous species often need to be
optimized for high-level expression in the vaccine strain.
It may also be desirable to add DNA sequences specify-
ing 5′ and 3′ untranslated mRNA sequences that create
stem-loop structures and to remove potential targets
within the coding mRNA sequences to minimize
mRNA degradation by the mRNA degradosome (47).
Deletion of the gene for poly(A) polymerase I can also
increase mRNA stability (48) to possibly improve the
productive fitness of the recombinant vaccine strain.
The stability of the synthesized antigen in the bacte-
rial antigen delivery strain must be considered, in order
to preclude toxicity of breakdown products as well as,
after delivery to the immunized host, to enhance induc-
tion of the desired type of immune response. Thus, T
cell antigens, which must be degraded by the proteo-
some prior to antigen presentation, might benefit from
changes that decrease their stability. Conversely, anti-
gens to which a humoral immune response is desired
should be engineered for greater stability in the immu-
nized host. Attention to the N-end rule for protein
degradation (49) and the presence of PEST sequences
(50) and other protease cleavage sites in the antigen can
help in design considerations. If the foreign antigen
contains cysteine residues, one must be concerned
about anomalous protein folding, which can be recti-
fied by deletion of Cys-encoding sequences, changing
of the environment of the antigen delivery strain with
regard to Eh potential, inclusion of a chaperone for the
expressed antigen, or modification of the dsb system for
isomerization of proteins with disulfide bonds (51).
Another means to enhance immunogenicity of an
expressed protective antigen might be inclusion of
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sequences leading to lipidation, since lipoproteins can
be taken up more efficiently by antigen-presenting cells
to induce an array of desired immune responses (52).
Since expression of proteins with extensive hydropho-
bic domains very often results in toxicity to the antigen
delivery vector, deleting of these sequences should be
considered, since immune responses to them are sel-
dom protective. Fusion of proteins to facilitate the
secretion of protective antigens (3, 11), or their delivery
to the cytoplasm by type III secretion systems to stim-
ulate T cell immunity (12), has been considered in sev-
eral cases. Such fusions can also be used to stabilize
proteins or to enhance induction of immune respons-
es by the fusion partner encoding a strong or universal
epitope. Coexpression of cytokines along with anti-
genic sequences might be helpful as well, since many of
these factors can be synthesized and secreted in a bioac-
tive form from recombinant attenuated bacterial anti-
gen delivery strains.
Evaluation in animals prior to human testing
Attaining the ultimate goal of vaccines that are safe
and efficacious in humans can be both advanced and
hindered by studies in animal systems. For example,
the use of S. typhimurium in mice as a surrogate for S.
typhi in humans has many real advantages. On the
other hand, the disease caused by S. typhimurium in
mice is not exactly the same as that caused by S. typhi
infection in humans. To make matters worse, most sci-
entists rely on mice that are inbred rather than out-
bred and that possess unique susceptibility to S.
typhimurium infection. Similarly, use of outbred mice
to evaluate candidate recombinant attenuated S. typhi
vaccines is likely very misleading. Evaluation of S. typhi
attenuation has often employed intraperitoneal inoc-
ulation of outbred mice in the presence of hog gastric
mucin (53). This assay seems to have worked very well
for attenuated strains with aro mutations that pre-
clude growth of the S. typhi but would lead one to
believe that bacteria with phoPQ deletions are as viru-
lent as wild-type bacteria, since their growth is not
impeded and the mice succumb to endotoxic shock
after growth of the S. typhi strain (54). It is also well
known that S. typhi is unable to survive in murine
macrophages of diverse types, and therefore the
immunogenicity of S. typhi constructs after intranasal
inoculation into mice is probably no different from
that achieved by a diversity of pathogens that are
unable to cause lethal infection in mice regardless of
whether attenuating mutations are present. The devel-
opment of strains of mice with enhanced susceptibili-
ty to S. typhi might overcome these problems. In this
regard, the recent generation of transgenic mice with
a receptor allowing L. monocytogenes infection via oral
inoculation (55) might provide a better model for
development of recombinant attenuated L. monocyto-
genes vaccines for humans. Work toward development
of improved M. tuberculosis–derived recombinant vac-
cines necessitates the discovery of attenuated M. tuber-
culosis strains unable to establish latent infections.
Nevertheless, results from tests of vaccine candidates
in mice or guinea pigs probably will not be reflective
of responses in humans. Therefore, more studies on
these various vaccine candidates must be conducted
with human volunteers.
Conclusion
Progress in the development of attenuated bacterial
vaccines to control diseases caused by those bacterial
pathogens in humans is encouraging. The ultimate
benefit, however, is likely to be achieved by the use of
some of these attenuated bacterial vaccines, or modi-
fied derivatives thereof, to express antigens from other
pathogens to induce protective immunity to those
pathogens. Use of live recombinant attenuated bacter-
ial antigen delivery systems would be akin to immu-
nization of the individual with a vaccine factory, since
production of the protective antigen and its presenta-
tion to the immunized individual occur in vivo after
immunization. Such vaccines are inexpensive to man-
ufacture and can be lyophilized to be reconstituted at
the time of use, thus likely avoiding the necessity of
refrigeration. Their oral or intranasal administration
eliminates the need for reliance on syringes with their
inherent added cost and association with accessory
unwanted hazards. Potential problems associated with
repeated use of the same or similar antigen delivery vec-
tors for the delivery of different protective antigens
require further careful study and might necessitate
modification of surface antigen attributes on the anti-
gen delivery vectors.
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